RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
 Infectious Diseases
  Brain Diseases
  Demyelinating Diseases
   Multiple Sclerosis
  Neurodegenerative Diseases
  Spinal Cord Diseases
  Trigeminal Neuralgia
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Multiple Sclerosis Channel

subscribe to Multiple Sclerosis newsletter
Latest Research : Neurosciences : Demyelinating Diseases : Multiple Sclerosis

   EMAIL   |   PRINT
Leptin's Role in Multiple Sclerosis

Mar 30, 2005 - 6:45:00 AM
The role of leptin in the pathogenesis of human MS is not fully understood. The authors studied 126 naïve-to-therapy, relapsing–remitting MS patients and detected an increase in leptin in both their cerebrospinal fluid and serum.

[RxPG] According to Giuseppe Matarese et al., increased levels of the cytokine-like hormone leptin in individuals with multiple sclerosis (MS) inversely correlates with the frequency of CD4+CD25+ regulatory T cells (TRegs).

Previous research has shown that leptin plays a significant role in the pathogenesis of autoimmune diseases such as experimental autoimmune encephalomyelitis, an animal model for MS.

The role of leptin in the pathogenesis of human MS is not fully understood. The authors studied 126 naïve-to-therapy, relapsing–remitting MS patients and detected an increase in leptin in both their cerebrospinal fluid and serum.

This increase correlated with elevated IFN-γ levels. Matarese et al. generated T cell lines from three of the individuals and, after activating the cells with human myelin basic protein, found an increase in leptin production and up-regulation of the leptin receptor.

Antileptin or an antileptin receptor blocking antibody inhibited the proliferative response of these T cells by up to 60%. Immunophenotypic analysis of peripheral blood from the MS patients showed a significant reduction in percentage and absolute number of TRegs, whereas no difference was observed in the frequency of other cell subpopulations. Treatment of experimental autoimmune encephalomyelitis mice with leptin antagonists increased the percentage of TRegs and slowed disease progression.

Publication: "Leptin increase in multiple sclerosis associates with reduced number of CD4M+CD25+ regulatory T cells" by Giuseppe Matarese, Pietro Biagio Carrieri, Antonio La Cava, Francesco Perna, Veronica Sanna, Veronica De Rosa, Daniela Aufiero, Silvia Fontana, and Serafino Zappacosta
On the web: Read the full text of this article 

Advertise in this space for $10 per month. Contact us today.

Related Multiple Sclerosis News
Smoking associated with rapid progression of multiple sclerosis
Testosterone may help men with multiple sclerosis
Age of onset but not severity of Multiple Sclerosis inherited from parents
Cause of nerve fiber damage in multiple sclerosis identified
Fampridine may hold promise for treating Multiple Sclerosis
CNS can send out signals to invite autoimmune attacks
Natalizumab Re-approved for Relapsing Multiple Sclerosis
Efficacy in relapse rate reduction beyond five years shown for interferon beta 1b in Multiple Sclerosis
Systematic Review Questions Accuracy of MRI in Multiple Sclerosis
Statins could prove useful in treating MS

Subscribe to Multiple Sclerosis Newsletter

Enter your email address:

 Additional information about the news article
Proceedings of the National Academy of Sciences of the United States of America

PNAS is one of the world's most-cited multidisciplinary scientific serials. Since its establishment in 1914, it continues to publish cutting-edge research reports, commentaries, reviews, perspectives, colloquium papers, and actions of the Academy. Coverage in PNAS spans the biological, physical, and social sciences. PNAS is published weekly in print, and daily online in PNAS Early Edition. The PNAS impact factor is 10.3 for 2003. PNAS is available by subscription.

PNAS is abstracted and/or indexed in: Index Medicus, PubMed Central, Current Contents, Medline, SPIN, JSTOR, ISI Web of Science, and BIOSIS.

Please note that the articles in PNAS report original research by independent authors and do not necessarily represent the views of the National Academy of Sciences or the National Research Council.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)